Skip to content
Home
Fibrocor Therapeutics
Search
  • About
    • Overview
    • Executive Team
    • Board of Directors
    • Clinical Advisory Board
  • Programs
    • Areas of Focus
    • Pipeline
  • Resources
  • Newsroom
    • Press Releases
    • Publications
    • Archives
    • YouTube
    • LinkedIn
  • Investors
  • Careers
    • Postings
      • Submit Your Application
        • Contact Us Form
  • Contact
Fibrocor Therapeutics
Search Toggle menu

Alport Syndrome Foundation

Alport Syndrome Foundation

What is Alport Syndrome?

Alport Syndrome A-Z

Alport Syndrome Foundation

Resource Library

Alport

Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome

Kidney Allograft Fibrosis

Advances and challenges in kidney fibrosis Nature review

2025 Vaulet et al Phenotypic spectrum of Kidney Transplant Rejection

2024 Aggarwal et al Science SOX9 regeneration to fibrosis in kidney sc level

2020 Saritas and Kramann KAF Diagnostic & Therapeutic Strategies

2019 Cippa et al B cell action post-transplant injury fibrosis

2012 Naesens Chronic historic damage Early Risk Factor for Late KAF


661 University Ave, Suite 1300
Toronto, Ontario, Canada M5G 0B7
+1 647-243-5296
info@fibrocor.com

Fibrocor Therapeutics Europe BV
1000 Brussels, Place des Barricades 13
Brussels Business Court
Brussels, Belgium


LinkedIn


YouTube
Copyright © 2025 Fibrocor Therapeutics, Inc
Fibrocor Therapeutics
Close menu
  • About
    • Overview
    • Executive Team
    • Board of Directors
    • Clinical Advisory Board
  • Programs
    • Areas of Focus
    • Pipeline
  • Resources
  • Newsroom
    • Press Releases
    • Publications
    • Archives
    • YouTube
    • LinkedIn
  • Investors
  • Careers
    • Postings
      • Submit Your Application
        • Contact Us Form
  • Contact